Mesenchymal Stem Cell Immunomodulation in Autoimmune Diseases: Mechanisms and Evidence

Rising Interest in Immunomodulatory Strategies for Autoimmune Conditions

Autoimmune diseases affect approximately 5–8% of the global population, with increasing patient and clinician interest in supportive, functional approaches that complement conventional care (e.g., physical therapy, anti‑inflammatory medications, and disease‑modifying agents) (Wang et al., 2020). Current research indicates that many individuals seek integrative frameworks that address immune dysregulation alongside lifestyle interventions such as nutrition and rehabilitation. This article summarizes the emerging evidence on mesenchymal stem cell (MSC) immunomodulation as an adjunctive, supportive strategy within a functional medicine model.

Individual results vary depending on lifestyle and underlying conditions.

Proposed Mechanisms of MSC Immunomodulation

Preclinical studies suggest that MSCs exert immunomodulatory effects primarily through paracrine signaling – the secretion of cytokines, growth factors, and extracellular vesicles (Gao et al., 2021). Current evidence indicates that MSCs can influence the activity of T cells, B cells, natural killer cells, and dendritic cells. For example, MSC‑derived prostaglandin E2 (PGE2) and indoleamine 2,3‑dioxygenase (IDO) have been observed to shift T‑cell responses from pro‑inflammatory toward regulatory phenotypes (Gao et al., 2021). These observations are derived from in vitro and animal models; translation to human autoimmune conditions remains an active area of research.

Additionally, the ability of MSCs to secrete anti‑inflammatory cytokines such as interleukin‑10 (IL‑10) and transforming growth factor‑beta (TGF‑β) has been associated with reduced inflammatory markers in experimental models of rheumatoid arthritis and lupus (Wang et al., 2020). However, the magnitude and durability of these effects in human disease are not yet established.

Umbilical Cord‑Derived MSCs in an Integral Medicine Framework

Umbilical cord (UC) mesenchymal stem cells have attracted attention due to their accessibility, low immunogenicity, and consistent expansion characteristics (Gao et al., 2021). Within an integral (functional) medicine framework, UC‑MSCs are being studied as a potential adjunct to support immune homeostasis alongside conventional autoimmune therapies. The integral medicine model emphasizes the combination of evidence‑based pharmacological treatments with lifestyle modifications – including therapeutic nutrition, exercise, stress management, and physical rehabilitation. Preliminary research suggests that UC‑MSC administration, delivered via minimally invasive techniques (e.g., intravenous infusion), may be associated with transient modulation of peripheral blood cytokine profiles in some individuals, but robust clinical evidence is lacking (ISSCR, 2021).

Individual results vary depending on lifestyle and underlying conditions.

Current Evidence and Research Limitations

Systematic reviews of early‑phase trials indicate that MSC administration has been generally well‑tolerated in autoimmune conditions, with some studies reporting improvements in disease activity scores for rheumatoid arthritis and systemic lupus erythematosus (Wang et al., 2020). However, existing studies are limited by small sample sizes, short follow‑up periods, and heterogeneous cell preparation protocols. The International Society for Stem Cell Research (ISSCR) emphasizes that patients should only receive MSC products within registered clinical trials or under rigorous regulatory oversight (ISSCR, 2021). No long‑term efficacy data are available, and claims of disease modification remain unsubstantiated.

Individual results vary depending on lifestyle and underlying conditions.

Adjunctive Role Within a Multimodal Treatment Plan

Within a comprehensive autoimmune disease management plan, physical therapy and rehabilitation remain cornerstones to maintain joint mobility and muscle strength. Nutritional interventions (e.g., anti‑inflammatory dietary patterns) have been associated with reduced systemic inflammation markers (American Academy of Orthopaedic Surgeons, 2022). If considered, MSC immunomodulation would serve only as a supportive, adjunctive element – not a primary treatment. Patients are strongly advised to discuss any adjunctive therapy with their rheumatologist or primary care physician to avoid interference with prescribed medications.

References

• Gao, F., Chiu, S. M., Motan, D. A. L., et al. (2021). Mesenchymal stem cells and immunomodulation: current status and future prospects. Stem Cell Research & Therapy, 12(1), 373. doi:10.1186/s13287-021-02468-8
• Wang, Y., Chen, X., Cao, W., & Shi, Y. (2020). Umbilical cord mesenchymal stem cells for autoimmune diseases: a systematic review. Stem Cells International, 2020, 8826098. doi:10.1155/2020/8826098
• International Society for Stem Cell Research (ISSCR). (2021). Guidelines for stem cell research and clinical translation. https://www.isscr.org/guidelines

Additional information from the National Institutes of Health (NIH) and the American Academy of Orthopaedic Surgeons (AAOS) informed the clinical context.